Semaglutide vs Tirzepatide: How Their Side Effects Compare (2026)

Semaglutide and tirzepatide are the two most-prescribed incretin medicines, and their side-effect profiles look more alike than different: both are dominated by gastrointestinal effects — nausea, vomiting, diarrhea, and constipation — plus fatigue, and both carry the same class warnings, including the thyroid C-cell tumor boxed warning, pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, and dehydration-related kidney injury.^[1][2][3][4] The biggest mechanistic difference is that semaglutide is a single GLP-1 receptor agonist (sold as Ozempic and Wegovy) while tirzepatide is a dual GIP/GLP-1 receptor agonist (sold as Mounjaro and Zepbound) — and tirzepatide produces greater average weight loss in trials.^[5][6] When the two were compared directly in the head-to-head SURPASS-2 trial, their gastrointestinal tolerability was broadly similar.^[5] This guide compares their side effects honestly — what overlaps, what differs, and why "better tolerated" is ultimately person-specific. It is general educational information, not medical advice.

The short answer: a shared profile, a different molecule

Semaglutide and tirzepatide belong to the same broad family of incretin-based medicines, and that family connection is why their side effects rhyme. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist, adding activity at a second incretin receptor.^[1][3] Despite that difference, both drugs slow gastric emptying and act on appetite and glucose pathways in overlapping ways, so both produce a side-effect picture dominated by the gut.^[1][3]

What is not the same is the average degree of weight loss. In its pivotal obesity trial, semaglutide 2.4 mg (Wegovy) produced substantial average weight loss; tirzepatide, in its own pivotal obesity trial and in the head-to-head diabetes trial against semaglutide, produced greater average reductions.^[5][6] Greater efficacy and a similar side-effect profile is the core trade-off people weigh — but, as the rest of this guide stresses, the individual experience varies widely, and the right choice is a prescriber-guided, person-specific decision rather than a verdict that one drug is universally "easier."

Side-by-side: the common gastrointestinal reactions

The table below lines up the most common adverse reactions reported in the labels of each drug. Read it carefully: these figures come largely from separate trials with different patient populations (type 2 diabetes versus weight management), different doses, and different study designs, so the columns are not directly comparable as head-to-head rates. The one truly direct comparison is SURPASS-2, summarized below the table. Use the table to see the shared pattern — GI symptoms on top, then fatigue — not to declare a precise winner.

The takeaway from the labels is that the menu of common side effects is essentially the same for both molecules — a GI-dominated list led by nausea, diarrhea, vomiting, and constipation, with fatigue and reduced appetite alongside.^[1][2][3][4] For most people, these reactions are dose- and titration-dependent: they tend to be heaviest in the first weeks and right after each dose increase, then ease as the body adapts.

The head-to-head: what SURPASS-2 actually showed

Because separate trials are not directly comparable, the most useful single piece of evidence is SURPASS-2 — a randomized phase 3 trial that pitted tirzepatide directly against semaglutide (1 mg, the diabetes dose) in adults with type 2 diabetes on metformin.^[5] On efficacy, tirzepatide produced greater reductions in A1C and body weight than semaglutide across its dose levels.^[5]

On tolerability, the headline is reassuring for anyone worried that the more powerful drug would be far harder to take: the gastrointestinal side-effect profiles were broadly similar between tirzepatide and semaglutide, with nausea, diarrhea, and vomiting the most common adverse events in both arms and most cases mild-to-moderate and concentrated during dose escalation.^[5] In other words, in the one place the two drugs were tested side by side, tirzepatide delivered more weight loss without a dramatically worse GI burden than semaglutide. That said, SURPASS-2 was a diabetes trial at the diabetes dose of semaglutide (1 mg) rather than the higher 2.4 mg weight-management dose, so it does not settle every tolerability question for the obesity setting.^[5]

The serious risks — identical class warnings

Beyond the common GI effects, both drugs carry the same set of serious class warnings in their prescribing information. This is where "they're basically the same" is most literally true: the warning sections of the Ozempic, Wegovy, Mounjaro, and Zepbound labels read very similarly.^[1][2][3][4]

• Boxed warning — thyroid C-cell tumors. Both semaglutide and tirzepatide carry a boxed warning about the risk of thyroid C-cell tumors based on rodent data, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[1][3]
• Pancreatitis. Both labels warn about acute pancreatitis and advise stopping the drug and evaluating if it is suspected.^[1][3]
• Gallbladder disease. Both warn about gallbladder problems, including gallstones, which can accompany rapid weight loss.^[2][4]
• Hypoglycemia with insulin or a sulfonylurea. On their own, both carry a low risk of low blood sugar, but that risk rises substantially when either is combined with insulin or an insulin secretagogue such as a sulfonylurea — a setting where the prescriber may lower the dose of the other drug.^[1][3]
• Acute kidney injury from dehydration. Both warn that the fluid losses from nausea, vomiting, and diarrhea can lead to dehydration and, occasionally, acute kidney injury — which is why hydration is a genuine safety measure, not just comfort.^[1][3]
• Other shared warnings. Both labels also address hypersensitivity reactions and other class-level cautions in their Warnings and Precautions sections.^[1][3]

Where they differ on safety: the retinopathy signal

The most-discussed point of divergence is diabetic retinopathy. In the semaglutide cardiovascular outcomes trial SUSTAIN-6, a higher rate of diabetic retinopathy complications was observed in the semaglutide group, and this signal is reflected as a precaution in the semaglutide labeling.^[7] The leading hypothesis is that it relates to the magnitude and speed of glucose-lowering in people with pre-existing retinopathy — a known phenomenon with rapid glycemic improvement — rather than a unique toxic effect, but the precaution stands and warrants attention in anyone with established eye disease.^[7]

This is one reason the comparison is not perfectly symmetrical, and it is a point to raise with a prescriber if you have a history of diabetic retinopathy. It should be weighed alongside everything else — it does not by itself make one drug categorically "safer," because the overall risk picture, your other conditions, and your tolerance all matter. The honest framing is that the two drugs share the great majority of their risk profile, with retinopathy being the clearest labeled distinction.^[1][3][7]

"Better tolerated" is person-specific

It is tempting to want a single answer to "which one has fewer side effects," but the evidence does not support a universal verdict. The profiles are similar, the head-to-head GI tolerability was broadly comparable, and individual responses vary widely.^[5] Some people sail through one drug and struggle with the other; the difference often comes down to titration pace, individual gut sensitivity, what other medications you take, and your own metabolic response — not the molecule alone.

Practical principles that apply to both drugs and tend to matter more than the brand on the pen:

• Slow titration is your friend. Both drugs are escalated in steps, and side effects peak right after each step-up. A prescriber can hold you at a dose longer before increasing if a rung is rough; slower titration is allowed and is the labels' intended response to poor tolerability.^[1][3]
• Hydrate and replace electrolytes, especially during any nausea, vomiting, or diarrhea — this both eases symptoms and guards against the dehydration-related kidney risk.^[1][3]
• Eat regular, protein-forward meals even when appetite is suppressed, and favor smaller, blander meals while nausea is active.
• Tell your prescriber what isn't going away. Persistent or severe GI symptoms, signs of dehydration or low blood sugar, severe abdominal pain (a pancreatitis red flag), or new vision changes (especially with a retinopathy history) warrant a call.^[1][3][7]
• The choice is individualized. Efficacy goals, your other conditions, insurance and supply, and how you tolerate the first doses all feed the decision — which is exactly why it belongs with a prescriber who follows up.

For the molecule-by-molecule detail, see our Ozempic side effects guide, and the Ozempic and Mounjaro drug pages. The bottom line: these are two members of the same family with a shared, GI-dominated side-effect profile and identical boxed warnings; tirzepatide tends to deliver more weight loss with broadly similar GI tolerability in the one head-to-head trial, semaglutide carries the clearer retinopathy precaution, and the "right" one is the one you tolerate under proper supervision.